MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based …
Over the last 12 months, insiders at MiNK Therapeutics, Inc. have bought $0 and sold $0 worth of MiNK Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at MiNK Therapeutics, Inc. have bought $5.86M and sold $94,850 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 429 shares for transaction amount of $472 was made by AGENUS INC (10 percent owner) on 2023‑10‑16.
2023-10-16 | 10 percent owner | 429 0.0012% | $1.10 | $472 | -15.45% | |||
2023-10-13 | 10 percent owner | 19,373 0.0561% | $1.10 | $21,310 | -15.45% | |||
2023-10-12 | 10 percent owner | 3,173 0.0089% | $1.10 | $3,488 | -18.41% | |||
2023-10-04 | 10 percent owner | 15,001 0.0465% | $1.09 | $16,380 | -17.59% | |||
2023-08-29 | 10 percent owner | 29,678 0.0826% | $1.52 | $45,016 | -38.68% | |||
2023-08-28 | 10 percent owner | 12,808 0.0371% | $1.45 | $18,570 | -33.00% | |||
2023-08-24 | 10 percent owner | 170,244 0.4482% | $1.54 | $262,908 | -37.33% | |||
2023-05-11 | 10 percent owner | 23,361 0.0606% | $1.43 | $33,348 | -34.57% | |||
2023-05-10 | 10 percent owner | 22,065 0.0649% | $1.51 | $33,296 | -29.80% | |||
2023-05-05 | Sale | director | 100,000 0.1767% | $0.95 | $94,850 | -31.96% | ||
2023-05-05 | 10 percent owner | 100,200 0.1772% | $0.95 | $95,100 | -31.96% | |||
2023-05-05 | 10 percent owner | 200 0.0005% | $1.25 | $250 | -31.96% | |||
2023-05-04 | 10 percent owner | 21,473 0.0618% | $1.22 | $26,246 | -13.80% | |||
2023-05-03 | 10 percent owner | 128,689 0.3494% | $1.08 | $138,843 | -7.69% | |||
2023-05-02 | director | 100,000 0.3138% | $0.95 | $94,850 | +21.35% | |||
2022-07-18 | 3,339 0.0098% | $1.33 | $4,438 | +60.45% | ||||
2021-10-19 | 10 percent owner | 1.4M 4.2248% | $12.00 | $16.8M | -79.46% |
AGENUS INC | 10 percent owner | 21772863 55.0658% | $0.68 | 14 | 0 | <0.0001% |
ARMEN GARO H | director | 1866400 4.7203% | $0.68 | 1 | 1 | +21.35% |
WIINBERG ULF | 281639 0.7123% | $0.68 | 1 | 0 | +60.45% |
The Vanguard Group | $212,708.00 | 0.6 | 234,182 | 0% | +$0 | <0.0001 | |
Longbow Finance Sa | $151,383.00 | 0.42 | 166,666 | 0% | +$0 | 0.02 | |
Renaissance Technologies | $96,000.00 | 0.27 | 105,228 | +14.33% | +$12,030.56 | <0.0001 | |
Geode Capital Management | $80,727.00 | 0.23 | 88,856 | -1.45% | -$1,188.34 | <0.0001 | |
BlackRock | $69,165.00 | 0.19 | 76,148 | -0.4% | -$280.66 | <0.0001 |